# Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

> **NCT07515625** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 46 (estimated)

## Conditions studied

- Gastric Cancer (GC)
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Bevacizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT07515625
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07515625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07515625, "Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07515625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*